Nanjing Medlander Medical Technology Co. Ltd. A (688273) — Cash Flow Reinvestment Rate

Latest as of December 2024: 3.85x

Nanjing Medlander Medical Technology Co. Ltd. A (688273) has a Cash Flow Reinvestment Rate of 3.85x as of December 2024, reinvesting CN¥471.54 Million (capex CN¥129.71 Million plus investments CN¥-341.83 Million) from operating cash flow of CN¥122.51 Million. Check how high is Nanjing Medlander Medical Technology Co.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

3.85x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥471.54 Million
Capex + Investments

Operating Cash Flow

CN¥122.51 Million
CNY

Capital Expenditures

CN¥129.71 Million
CNY

Nanjing Medlander Medical Technology Co. Ltd. A Cash Flow Reinvestment Rate (2020–2024)

Historical reinvestment intensity for Nanjing Medlander Medical Technology Co. Ltd. A across 5 annual periods. Explore Nanjing Medlander Medical Technology Co. (688273) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Nanjing Medlander Medical Technology Co. Ltd. A (2020–2024)

Year-by-year capital reinvestment analysis for Nanjing Medlander Medical Technology Co. Ltd. A. For live market cap and broader valuation context, see 688273 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 3.85x CN¥471.54 Million CN¥122.51 Million CN¥129.71 Million ▲ +131.6%
2023 1.66x CN¥227.50 Million CN¥136.91 Million CN¥75.15 Million ▲ +49.7%
2022 1.11x CN¥140.57 Million CN¥126.67 Million CN¥54.26 Million ▲ +607.4%
2021 0.16x CN¥23.31 Million CN¥148.60 Million CN¥14.58 Million ▼ -59.2%
2020 0.38x CN¥50.41 Million CN¥131.10 Million CN¥25.91 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow